Humanized Immune System Mouse Models

GemPharmatech’s humanized immune system mice enable researchers to evaluate human immune responses in vivo. Our huHSC and huPBMC models support immuno-oncology, autoimmune and infectious disease research, and preclinical drug development.

Browse Models

Why Us

Featured Models

Humanized Immune System Mouse Models

Selected huPBMC and huHSC mouse models for studying human immune responses and evaluating therapeutics across immuno-oncology and other immune-mediated diseases.

Humanized Immune System Mouse Models

Browse available humanized immune system mouse strains for immuno-oncology, autoimmune disease, infectious disease, and preclinical drug development.

Product Models

Hidden field

ModelStatusStrain NumberArea of research

res?.all_product?.table_th_info

FAQ

Frequently Asked Questions About Humanized Immune System Mice

Why are female mice commonly used as recipients for immune system reconstitution?

Breeding management: Male mice require single housing to prevent fighting, whereas female mice can be group-housed, significantly reducing cage space requirements. Handling and tolerance: Female mice are generally more docile, facilitating long-term tail vein injection and serial blood sampling. Immune profile and hormonal stability: Compared with males, female mice exhibit more stable immune system reconstitution with superior engraftment efficiency under equivalent conditions.

What are the core advantages of the humanized immune system huHSC-NCG mouse model?

Ready-to-use: single batch delivery capacity of over 500 mice. Stable & Reliable: Pre-tested, meets industry reconstitution benchmark (hCD45+ ≥ 25%). Extended Survival: Over 90% survival rate at 250 days (35+ weeks) post huHSC reconstitution, ideal for long-term studies including toxicology and safety assessment. Proprietary model with high-impact literature support (total IF > 5000), data available on official website.

What are the differences of huPBMC-NCG and huHSC-NCG?

The core advantage of huPBMC-NCG lies in its rapid, T cell-focused reconstitution, enabling high-efficiency acquisition of human T cell experimental data within 7–14 days. It is suitable for short-term CDX/PDX models and the construction of autoimmune disease models using patient-derived PBMC/PBL. In contrast, huHSC-NCG is characterized by its comprehensive and long-lasting reconstitution, achieving multi-lineage and multi-organ hematopoietic reconstitution over 8–12 weeks. It is applicable to long-term CDX/PDX models, autoimmune and infection models (reconstitution combined with inducers), and features extended survival cycles with high stability, making it particularly suitable for long-term pharmacodynamic evaluation.

Explore